Special Issue "Drug Polymorphism and Dosage Form Design (Volume II)"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 30 November 2023 | Viewed by 1375

Special Issue Editors

School of Pharmacy, Drug Delivery Division, University of Camerino, CHIP Research, Camerino, Italy
Interests: pharmaceutical technology; formulation; biomaterials; hydrogels; nanoparticles; polymorphism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce the new Special Issue for Pharmaceutics entitled “Drug Polymorphism and Dosage Form Design”.

Extensive academic and industrial research demonstrated that more than 50% of the currently used APIs  shows multiple physical arrangement of the constituents in the crystal lattice. This polymorphism significantly influences a variety of drug properties, including dissolution rate, solubility, tabletability, flowability, stability and even bioavailability, efficacy and toxicity. Pioneered by Aguiar et al in the ‘60s, surprisingly, after many decades, this research area is still attracting much attention by the scientific community and motivated the edition of this Special Issue, that is aimed at gathering the most recent advances in the field of polymorphism, highlighting its relevance in the Pharmaceutical Sciences and in the Design of Dosage Forms.

Original research articles and review articles dealing with all the aspects of drug polymorphism are considered. Particularly, the discovery of new crystal forms, methods for their preparation, influence of the polymorphism on the physicochemical properties, analytical methods for the study of crystal forms, API stability during processing and storage, biological effects of polymorphism, preformulation studies, design of dosage forms and  regulatory implications are all included in this Special Issue.

Dr. Roberta Censi
Prof. Dr. Piera Di Martino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • amorphism
  • dissolution
  • polymorphism
  • dosage form
  • bioavailability
  • stability
  • mechanical properties
  • tabletability
  • flowability
  • analytical methods

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Virtual Screening, Structural Analysis, and Formation Thermodynamics of Carbamazepine Cocrystals
Pharmaceutics 2023, 15(3), 836; https://doi.org/10.3390/pharmaceutics15030836 - 03 Mar 2023
Cited by 3 | Viewed by 1145
In this study, the existing set of carbamazepine (CBZ) cocrystals was extended through the successful combination of the drug with the positional isomers of acetamidobenzoic acid. The structural and energetic features of the CBZ cocrystals with 3- and 4-acetamidobenzoic acids were elucidated via [...] Read more.
In this study, the existing set of carbamazepine (CBZ) cocrystals was extended through the successful combination of the drug with the positional isomers of acetamidobenzoic acid. The structural and energetic features of the CBZ cocrystals with 3- and 4-acetamidobenzoic acids were elucidated via single-crystal X-ray diffraction followed by QTAIMC analysis. The ability of three fundamentally different virtual screening methods to predict the correct cocrystallization outcome for CBZ was assessed based on the new experimental results obtained in this study and data available in the literature. It was found that the hydrogen bond propensity model performed the worst in distinguishing positive and negative results of CBZ cocrystallization experiments with 87 coformers, attaining an accuracy value lower than random guessing. The method that utilizes molecular electrostatic potential maps and the machine learning approach named CCGNet exhibited comparable results in terms of prediction metrics, albeit the latter resulted in superior specificity and overall accuracy while requiring no time-consuming DFT computations. In addition, formation thermodynamic parameters for the newly obtained CBZ cocrystals with 3- and 4-acetamidobenzoic acids were evaluated using temperature dependences of the cocrystallization Gibbs energy. The cocrystallization reactions between CBZ and the selected coformers were found to be enthalpy-driven, with entropy terms being statistically different from zero. The observed difference in dissolution behavior of the cocrystals in aqueous media was thought to be caused by variations in their thermodynamic stability. Full article
(This article belongs to the Special Issue Drug Polymorphism and Dosage Form Design (Volume II))
Show Figures

Figure 1

Back to TopTop